CN108143719A - A kind of nano liposomes for carrying polypeptide and its preparation method and application - Google Patents
A kind of nano liposomes for carrying polypeptide and its preparation method and application Download PDFInfo
- Publication number
- CN108143719A CN108143719A CN201711448230.4A CN201711448230A CN108143719A CN 108143719 A CN108143719 A CN 108143719A CN 201711448230 A CN201711448230 A CN 201711448230A CN 108143719 A CN108143719 A CN 108143719A
- Authority
- CN
- China
- Prior art keywords
- nano liposomes
- curcumin
- phosphatide
- cholesteryl ester
- nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 90
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 41
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 39
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 129
- 235000012754 curcumin Nutrition 0.000 claims abstract description 68
- 229940109262 curcumin Drugs 0.000 claims abstract description 65
- 239000004148 curcumin Substances 0.000 claims abstract description 65
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 63
- -1 cholesteryl ester Chemical class 0.000 claims abstract description 35
- 201000002491 encephalomyelitis Diseases 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 6
- 238000002474 experimental method Methods 0.000 claims abstract description 5
- 239000006185 dispersion Substances 0.000 claims abstract description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 239000000725 suspension Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 239000010408 film Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 239000000975 dye Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 210000002706 plastid Anatomy 0.000 claims description 5
- 239000010409 thin film Substances 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 5
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 3
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 claims description 3
- 241000234314 Zingiber Species 0.000 claims description 3
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 3
- 235000008397 ginger Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 239000000298 carbocyanine Substances 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000003139 buffering effect Effects 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 230000008685 targeting Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 40
- 238000002347 injection Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 19
- 238000011282 treatment Methods 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 13
- 210000003462 vein Anatomy 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 9
- 206010014599 encephalitis Diseases 0.000 description 9
- 230000006698 induction Effects 0.000 description 8
- 230000002269 spontaneous effect Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000025698 brain inflammatory disease Diseases 0.000 description 7
- 241000581650 Ivesia Species 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000002539 nanocarrier Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- 244000163122 Curcuma domestica Species 0.000 description 4
- 235000003392 Curcuma domestica Nutrition 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000003373 curcuma longa Nutrition 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 210000005012 myelin Anatomy 0.000 description 4
- 238000007665 sagging Methods 0.000 description 4
- 235000013976 turmeric Nutrition 0.000 description 4
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 108010081690 Pertussis Toxin Proteins 0.000 description 3
- 241000973497 Siphonognathus argyrophanes Species 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000009514 concussion Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000002074 inflammatory monocyte Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004493 neutrocyte Anatomy 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- NCWOMXABNYEPLY-NRPADANISA-N Glu-Ala-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O NCWOMXABNYEPLY-NRPADANISA-N 0.000 description 1
- NTBFKPBULZGXQL-KKUMJFAQSA-N Lys-Asp-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTBFKPBULZGXQL-KKUMJFAQSA-N 0.000 description 1
- AZOFEHCPMBRNFD-BZSNNMDCSA-N Lys-Phe-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 AZOFEHCPMBRNFD-BZSNNMDCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- CYZBFPYMSJGBRL-DRZSPHRISA-N Phe-Ala-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CYZBFPYMSJGBRL-DRZSPHRISA-N 0.000 description 1
- ULECEJGNDHWSKD-QEJZJMRPSA-N Phe-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 ULECEJGNDHWSKD-QEJZJMRPSA-N 0.000 description 1
- LHHDBONOFZDWMW-AAEUAGOBSA-N Trp-Asp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N LHHDBONOFZDWMW-AAEUAGOBSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical group C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108010074082 phenylalanyl-alanyl-lysine Proteins 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
- A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of nano liposomes for carrying polypeptide, are 30 containing molar ratio:(0.5~1):8 phosphatide, cholesteryl ester and polypeptide R4F；And a kind of nano liposomes for carrying curcumin, it is (5~10) containing molar ratio:30:(0.5~1):8 curcumin, phosphatide, cholesteryl ester and R4F.The preparation method of the nano liposomes is disclosed, uses the film dispersion method of existing liposome.Also disclose application of the nano liposomes in the drug for preparing Experiment on therapy spontaneity encephalomyelitis.The nano liposomes targeting is high, and physicochemical property is excellent, good biocompatibility, envelop rate are high and toxic side effect is low, can effective Experiment on therapy spontaneity encephalomyelitis.
Description
Technical field
The invention belongs to biomedicine field, more particularly to a kind of nano liposomes for carrying polypeptide and preparation method thereof and
Using.
Background technology
Nano liposomes are a kind of artificial membranes, and phospholipid molecule hydrophilic head is inserted into water in water, liposome hydrophobic tail
Air is stretched to, the spherical liposomes of double-deck fat molecule are formed after agitation, 25~1000nm of diameter is differed.Nano liposomes can be used for
Transgenosis or the drug for carrying preparation, especially the latter, as a kind of novel administering mode --- it can be with using liposome
Drug is sent into cell interior by the characteristics of cell membrane fusion, and the nano liposomes of carrying medicaments function are just gradually closed by people
Note.The pattern of nano liposomes carrying medicaments changes existing drug delivery formats, solves most of hydrophobic drug indissoluble
The problems such as property is low with utilization rate.There is relevant report to be used for different diseases using class such as PLGA nano liposomes packaging medicine at present
The treatment of disease, achieves certain curative effect.In terms of the treatment such as treatment of encephalitis of inflammation class, also begin to wrap up using nano liposomes
Drug.But since nano liposomes lack targeting specific, cause passive target uptake ratio low, and big due to nano-carrier
Problems of Grain Size can not effectively be distributed in entire affected part, and then cause therapeutic effect not ideal enough.There is an urgent need for site-specific at present
Property, the nano liposomes of more effective carrying medicaments be used for the treatment of encephalitis.
Curcumin is a kind of polyphenol compound, is mainly extracted from plant turmeric, is a kind of dietotherapy drug.Curcumin
Specificity is inhibited to intracellular molecule NF- Κ β, and then effectively inhibits with the relevant inflammatory signals molecule ways of NF- Κ β
Diameter is capable of the generation of high degree inhibition inflammation, is widely concerned by people in past a period of time.However, as ginger
Three big shortcomings of flavine, cause clinical practice to be limited to；First shortcoming of curcumin is extremely low water solubility, curcumin
Maximum water solubility is 30nM, and the curcumin concentration to play a role is typically in a μM rank；Second shortcoming of curcumin be
Chemical instability in aqueous solution, it is easy to by oxidative metabolism；The third shortcoming of curcumin is extremely low cellular uptake rate,
Most of curcumin can be interspersed on cell membrane, but it is considerably less to infiltrate the amount to play a role into cytoplasm.If ginger can be overcome
These obstacles of flavine, it will curcumin is contributed to play a role in clinical treatment.
In conclusion a kind of nano liposomes that can be effectively targeted to brain inflammation class disease of exploitation, can improve and receive
Application of the Mizhi plastid in the clinical disease diagnosis especially medical diagnosis on disease of brain inflammation class；Develop a kind of ultra-small grain size, water
Dissolubility, can be effectively targeted to and treat brain inflammation class disease carrying curcumin nano liposomes, it will greatly
Promote application of the curcumin in the clinical disease treatment especially disease treatment of brain inflammation class.
Invention content
The technical problem to be solved by the present invention is to：Overcome nano liposomes targeting brain inflammation class disease effect in the prior art
The shortcomings that fruit is bad provides a kind of nano liposomes for targeting brain inflammation class disease；More preferably, overcome turmeric in the prior art
The shortcomings that element is insoluble in that water, unstable, cellular uptake rate is low, and clinical therapeutic efficacy is undesirable, providing one kind can be effective
Treatment brain inflammation class disease nano liposomes for carrying curcumin and its preparation method and application.
One of technical solution is used by present invention solution above-mentioned technical problem：
A kind of nano liposomes for carrying polypeptide, it is 30 that the nano liposomes, which include molar ratio,:(0.5~1):8 phosphorus
Fat, cholesteryl ester and target polypeptide, the target polypeptide are R4F of the amino acid sequence as shown in SEQ ID NO.1.
Preferably, the nano liposomes further include lipophilicity carbonyl cyanine dye；Preferably, the lipophilicity carbocyanine
Dyestuff, phosphatide, cholesteryl ester and R4F molar ratio be 2:30:1:8.
One of technical solution is used by present invention solution above-mentioned technical problem：
A kind of nano liposomes for carrying polypeptide, which is characterized in that the nano liposomes further include curcumin, described
The molar ratio of curcumin and phosphatide, cholesteryl ester and R4F is (5~10):30:(0.5~1):8.Preferably, the nano-lipid
Body is made of curcumin, phosphatide, cholesteryl ester and R4F.
According to general knowledge known in this field, the component of liposome mainly include being formed the phosphatide of liposome bilayers structure with
And change cholesterol/cholesteryl ester substance of membrane fluidity.Wherein, active constituent is relative to phosphatide and the ratio of cholesteryl ester substance
Example is lower, and envelop rate is better, but drugloading rate is low；Conversely, drugloading rate is high, but envelop rate may decline.Therefore the component of liposome,
Content and preparation method can influence envelop rate, drugloading rate, nanometer particle size of final products etc..
Wherein, curcumin ratio is too low, then influences the drugloading rate and curative effect of invented liposomes.Therefore it is highly preferred that institute
The mass ratio of curcumin, phosphatide, cholesteryl ester and R4F stated are 10:30:1:8.
Even more preferably, the phosphatide is dimyristoyl phosphatidyl choline；The cholesteryl ester is cholesterol
Oleate.
One of technical solution is used by present invention solution above-mentioned technical problem：
The preparation method of above-mentioned nano liposomes uses the film dispersion method of existing liposome.
According to the present invention, existing conventional method for preparing lipidosome may be used in nano liposomes, such as has membrane process, anti-
Phase evaporation, solvent injection method and multi-emulsion method etc..The present invention using be most original but be it is most basic so far and application most
Extensive film dispersion method, it is preferable that the preparation method of nano liposomes includes the following steps：
1) phosphatide and cholesteryl ester are dissolved in the container containing organic solvent, mixing resulting mixture；
2) mixture is made to form thin film in the container bottom；
3) buffer solution is added in, the drug film is fully resuspended, forms uniform suspension；
4) ultrasound becomes to the suspension and clarifies, and adds in polypeptide, mixing to obtain the final product.
Preferably, the phosphatide is dimyristoyl phosphatidyl choline, and the cholesteryl ester is cholesterol acid ester.
Preferably, the step 1) further includes addition curcumin, the curcumin and phosphatide, cholesteryl ester and R4F
Molar ratio is (5~10):30:(0.5~1):8；Preferably, the molar ratio of the curcumin, phosphatide, cholesteryl ester and R4F
It is 10:30:1:8；Preferably, the step further includes the free curcumin and polypeptide of 5) ultrafiltration removal；It is it is highly preferred that described super
Filter is carried out using 30KD super filter tubes.
Even more preferably, the organic solvent is chloroform；Preferably, the film is formed or by nitrogen drying with rotation
It is made after turning evaporation under reduced pressure evaporation organic solvent；It is highly preferred that the buffer solution is the phosphate buffer of pH6.5~7.5.
One of technical solution is used by present invention solution above-mentioned technical problem：
Application of the above-mentioned nano liposomes in the drug of diagnosis or Experiment on therapy spontaneity encephalomyelitis is prepared.
On the basis of common knowledge of the art, above-mentioned each optimum condition can be combined arbitrarily to get each preferable reality of the present invention
Example.
The reagents and materials used in the present invention are commercially available.
The positive effect of the present invention is：
1) targeting is good：The affected part of the selectively targeted brain inflammation of energy；2) physicochemical property is excellent：It is dissipated using dynamic laser light
The average grain diameter that shooting method measures nano liposomes is 15nm or so；3) good biocompatibility：Preparing the nano liposomes is made
Raw material all respectively for clinical or clinical test, has good biocompatibility；4) preparation process is simple, convenient for rule
Modelling produces；5) entrapment efficiency is more than 60%, meets《Pharmacopoeia of People's Republic of China》Requirement for microcapsule formulation；Pass through
The curcumin of doses with synthesizing the ingredient of nano liposomes is incubated, the water solubility of curcumin can be obviously improved,
Never transparence suspension liquid becomes clarifying shape suspension liquid；6) therapeutic effect is good：Have in the spontaneous encephalomyelitis of experiment compared with
Good therapeutic effect, it is thin to carry the related inflammatory that the nano liposomes of curcumin can be targeted efficiently using polypeptide R4F in blood
Born of the same parents are played a role by blocking related inflammation cell across blood-brain barrier；7) toxic side effect is low：Carry the nanometer fat of curcumin
Plastid, all material are all that clinical practice is common.Results of Animal is shown, carries the nano liposomes of curcumin
The generation of significantly Inhibition test spontaneity encephalomyelitis is capable of in treatment group, promotes the recovery of mouse weight；8) function can expand
Exhibition：Relevant disease can be targeted for highlighting curcumin by entrained polypeptide by carrying the nano liposomes carrier of curcumin
Clinical practice, while relevant dye molecule can be loaded in core for being imaged or the other related drugs of collaborative loading reach
The purpose of synergistic treatment, the effect of realizing the collaboration targeting or synergistic treatment of disease.
Description of the drawings
Fig. 1 is the overall structure figure for the nano liposomes for loading curcumin；
Fig. 2 is that curcumin is loaded into the nanometer particle size distribution system that nano liposomes are obtained by the method for dynamic light scattering
Meter；
Fig. 3 is the Detection of Stability for carrying the nano liposomes of curcumin under different incubation conditions, wherein No. 1 is normal
4 DEG C of environment；No. 2 are 3 hours environment in 37 DEG C；No. 3 are to be placed on 3 hours in 37 DEG C of 10% serum；No. 4 are to be placed on 37 DEG C
6 hours in 10% serum；No. 5 are to be placed on 6 hours in 37 DEG C of 10% serum；No. 6 are to be placed in 37 DEG C of 10% serum
10 hours；No. 7 are to be placed on 24 hours in 37 DEG C of 10% serum；
Fig. 4 is the influence for carrying the nano liposomes of curcumin under different injection dosages to EAE incidence；
Fig. 5 is to carry the nano liposomes of curcumin and the induction of corresponding control group processing method tail vein injection
Therapeutic effect statistics after EAE model mices, including counting (A) and mouse invasion situation statistics (B) to changes of weight；
Fig. 6 be carry curcumin nano liposomes treatment EAE model mices after to mouse brain carry out HE dyeing judge
Immunocyte Infiltrating；
Fig. 7 be carry curcumin nano liposomes treatment EAE model mices after to mouse spinal cord carry out LFB dyeing judge
Myelin damage situation；
Fig. 8 is to carry the nano liposomes of fluorescent dye DIRBOA (to have no apparent by tail vein injection EAE model mices
Clinical onset symptom) after imaging results for 24 hours, evaluate the diagnosis effect to disease；
Fig. 9 is the C57 mouse back brain ice for 24 hours for the nano liposomes tail vein injection induction EAE models for carrying curcumin
Freeze slice immunofluorescence results.
Specific embodiment
It is further illustrated the present invention below by the mode of embodiment, but does not therefore limit the present invention to the reality
It applies among a range.Test method without specific conditions in the following example, according to conventional methods and conditions or according to quotient
Product specification selects.
Embodiment 1 carries the preparation of the nano liposomes of polypeptide
Nano liposomes in the present embodiment, main composition is target polypeptide R4F, phosphatide, cholesterol acid ester,
Described in targeting peptides R4F sequence be FAEKFKEAVKDYFA KFWDGSG (SEQ ID No.1, from C57 Strains of Mouse marrows
Sheath antigen polypeptide), preparing the step of carrying the nano liposomes of polypeptide is：
1) 2mg dimyristoyl phosphatidyl cholines (DMPC) and 0.065mg cholesterol acid esters are filled in teat glass
Divide mixing, and shut test tube mouth with sealed membrane；
2) invisible spectro chloroform is dried up in stable nitrogen stream, enables the mixture in step 1) in test tube bottom
Form thin film；
3) test tube is put into vacuum desiccator and is dried in vacuo 1h；
4) phosphate buffer (pH 7.2) of 2ml is added in into test tube, it, will using vortex concussion instrument after being filled with nitrogen-sealed
The product film of test tube bottom is fully resuspended to form uniform suspension；
5) test tube is positioned over 42 DEG C of ultrasounds to suspension solution and becomes clarification；
6) PBS solution (pH9.0) containing 2mg polypeptides R4F is added in into the test tube of sealing using syringe, it is close after mixing
Envelope, 4 DEG C stand overnight.
7) next day concentrates sample using super filter tube (30KD, Merck), and 2500rpm is centrifuged under 4 DEG C of environment, is gone
Except free polypeptide up to phosphatide, cholesteryl ester and polypeptide molar ratio be 30:1:8 individual layer nano liposomes (HPPS), grain
Diameter is small and permeance property is good.
Embodiment 2 carries the preparation of the nano liposomes of curcumin
In the present embodiment, the nano liposomes of curcumin are carried, main composition is target polypeptide R4F, phosphatide, turmeric
Element, cholesterol acid ester, wherein the sequence of the targeting peptides R4F as shown in SEQ ID No.1, prepares the nanometer for carrying curcumin
The step of carrier is：
1) by 2mg dimyristoyl phosphatidyl cholines (DMPC), 0.065mg cholesterol acid esters (CO), 0.3mg curcumins
Chloroformic solution；It is sufficiently mixed in teat glass, and is shut test tube mouth with sealed membrane；
2) invisible spectro chloroform is dried up in stable nitrogen stream, enables the mixture in step 1) in test tube bottom
Form thin film；
3) test tube is put into vacuum desiccator and is dried in vacuo 1h；
4) phosphate buffer (pH 7.2) of 2ml is added in into test tube, it, will using vortex concussion instrument after being filled with nitrogen-sealed
The suspension to form uniform yellow is fully resuspended in the drug film of test tube bottom；
5) test tube is positioned over 42 DEG C of ultrasounds to suspension solution and becomes clarification；
6) PBS solution (pH9.0) containing 2mg target polypeptides R4F, mixing are added in into the test tube of sealing using syringe
After seal, 4 DEG C stand overnight；
7) next day concentrates sample using super filter tube (30KD, Merck), and 2500rpm is centrifuged under 4 DEG C of environment, is gone
Except free polypeptide and curcumin to get curcumin, phosphatide, cholesteryl ester and polypeptide molar ratio be 10:30:1:8th, grain size it is small and
The good individual layer nano liposomes (HPPS) of permeance property carry the HPPS- curcumins of curcumin.
Free curcumin solution is not soluble in water, is the opaque solution of suspension graininess yellow；And after wrapping up curcumin
Nano-lipid liquid solution be clear shape yellow solution.Nano liposomes overall structure obtained is as shown in Figure 1, wherein phosphorus
Fat forms the monofilm of liposome, and then R4F is embedded in phospholipid monolayer, and core loads curcumin and cholesterol ester.It is average
Grain size is detected using nanometer particle size potentiometric analyzer Zetasizer Nano-ZS90, as shown in Fig. 2, average grain diameter is
15.2±2.3nm.Envelop rate calculation formula：Drug is added in envelop rate=actual vector drug content/synthesis nano-carrier
Content calculates envelop rate=0.09~0.12mg/0.15mg=60%~80% of gained.Fig. 3 is the nanometer for carrying curcumin
Detection of Stability of the liposome under different incubation conditions, from 1~No. 6 result it is found that 10% blood of the nano liposomes at 37 DEG C
10 hours can keep stable in clear.
Embodiment 3 carries the preparation of the nano liposomes of DIRBOA
In the present embodiment, the nano liposomes of fluorescent dye DIRBOA (lipophilicity carbonyl cyanine dye), main composition are carried
Ingredient is target polypeptide R4F, phosphatide, DIRBOA, cholesterol acid ester, wherein the sequence of the targeting peptides R4F is such as SEQ ID
Shown in No.1, preparing the step of carrying the nano-carrier of DIRBOA is：
1) by 2mg dimyristoyl phosphatidyl cholines (DMPC), 0.065mg cholesterol acid esters (CO), 0.2mg
DIRBOA is dissolved in chloroformic solution；It is sufficiently mixed in teat glass, and is shut test tube mouth with sealed membrane；
2) invisible spectro chloroform is dried up in stable nitrogen stream, enables the mixture in step 1) in test tube bottom
Form thin film；
3) test tube is put into vacuum desiccator and is dried in vacuo 1h；
4) phosphate buffer (pH 7.2) of 2ml is added in into test tube, it, will using vortex concussion instrument after being filled with nitrogen-sealed
The film of test tube bottom is fully resuspended to form uniform suspension；
5) test tube is positioned over 42 DEG C of ultrasounds to suspension solution and becomes clarification；
6) PBS solution (pH9.0) containing 2mg target polypeptides R4F, mixing are added in into the test tube of sealing using syringe
After seal, 4 DEG C stand overnight；
7) next day concentrates sample using super filter tube (30KD, Merck), and 2500rpm is centrifuged under 4 DEG C of environment, is gone
Except free polypeptide and curcumin to get DIRBOA, phosphatide, cholesteryl ester and polypeptide molar ratio be 2:30:1:8 individual layer is received
Mizhi plastid HPPS-DIRBOA.
Embodiment 4 targets experimental spontaneous encephalomyelitis
The nano liposomes for carrying curcumin treat model to experimental spontaneous encephalomyelitis (EAE)：
The experimental spontaneous encephalomyelitis model of structure：Freund's adjuvant (5mg/mL inactivations combine mycobacteria) emulsification mouse
Self-polypeptide MOG35-55 (Mouse Neuron myelin antigen polypeptides, to disclose sequence, referring to Ingunn M Stromnes, et
al.Active induction of experimental allergic encephalomyelitis,Nature
Protocol, 2006), sequence is MEVGWYRSPFSRVVHL YRNGK, is synthesized by Shanghai Chu Tai bio tech ltd, in
Subcutaneous 4 points of injections, then carried out mouse tail vein injection pertussis toxin (PTX) in 0 hour and 24 hours.The inoculation date determines
Be the 0th day, date thereafter is denoted as the 1st respectively, 2,3 ... 19 days.Stratified random point was carried out to mouse as desired at the 9th day
Group, every group of quantity (are grouped the mouse that experimental spontaneous encephalomyelitis occurs) not less than 5.
Started tail vein injection at the 9th day；Co-injection 5 times；First each mouse is marked before injection, weighs the matter of each mouse
Amount, records in the table pre-established.
Control groups (blank control group) only need the PBS, injection volume 0.1ml/ that tail vein injection sterilizes when injecting
10g。
I.v.therapy groups (treatment group) need curcumin nano-lipid body, injection made from tail vein injection embodiment 2
Measure as 1.8mg, 0.9mg and 0.18mg turmeric cellulose content/kg mouse weights, volume injected for 0.1ml/10g mouse weights to get
HPPS-100nM curcumins as shown in Table 1, HPPS-50nM curcumins and HPPS-10nM curcumin groups.
NP Control groups (nano liposomes control group) using embodiment 1 carry the nano liposomes of polypeptide R4F as pair
According to the concentration of injection is determined according to peptide concentration, is consistent with the peptide concentration of Therapy groups.
Injection cycle is primary for every other day injection, totally 5 times.And the weight of mouse is measured every time and clinical
Behavior is assessed.It measured, every other day surveys once, measurement data record is in the table since the 9th day.Fig. 4 is commented for clinic
Point, as induction number of days increases and is gradually increasing, wherein HPPS-50nM groups and the scoring of HPPS-100nM groups is apparent for each group scoring
More other groups of score value is low.
The nano liposomes for carrying curcumin of 1 various concentration of table are counted for the therapeutic effect of EAE
The therapeutic effect for carrying the nano-carrier of curcumin is as shown in table 1, in HPPS-50nM curcumin groups, mouse invasion
Rate is 60%；In HPPS-100nM curcumin groups, mouse invasion rate is reduced to 40%, is controlled than HPPS-10nM curcumins group and control
Therapeutic effect is good.
The physiological status of mouse is weighed using mouse weight, as can be seen from Figure 5 tail vein injection HPPS-Curcumin
(curcumin) 100nmol effects are very good, are substantially able to maintain that mouse weight is constant (Fig. 5 A), and group treatment mouse
EAE models are also relatively more effective (Fig. 5 B).
The ratio that the inhibition inflammation generation for the nano liposomes for carrying curcumin is shown after 5 wheel treatments is 80%,
It increases significantly relative to other control groups, and score of falling ill drops to 1.5 from average 3.5, shown result such as Fig. 6 and 7 institutes
Show.Fig. 6 is the brain HE dyeing of the mouse by the treatment of different groups, for observing peripheral blood immunocyte Infiltrating,
The part of middle picture amplification is ventricle region and the site of immunocyte infiltration, it can be seen that by HPPS-Curcumin
The immunocyte infiltration of the mouse brain of 100nmol treatments is less.Fig. 7 is the spinal cord LFB for the mouse treated by different groups
Dyeing, for judging spinal nerve myelin damage degree, the result of Fig. 7 shows that the nano liposomes after adding in curcumin can be shown
The destruction for inhibiting immune system to myelin is write, maintains the integrality of neuron.
Morbidity score criterion：
0：Mouse is normal, without any abnormal behaviour
1：Mousetail is sagging
2：Mousetail is sagging+and mouse hind leg gradually paralyses
3：Mousetail is sagging+and mouse hind leg paralyses completely
4：Mousetail is sagging+and mouse hind leg paralyses+mouse fore-limb paralysis completely
5：Dead mouse
The early diagnosis of the experimental spontaneous encephalomyelitis of embodiment 5
The nano liposomes of fluorescent dye DIRBOA are carried to experimental spontaneous encephalomyelitis early diagnosis model：
The experimental spontaneous encephalomyelitis model of structure：Freund's adjuvant (5mg/mL inactivations combine mycobacteria) emulsification mouse
Self-polypeptide MOG35-55 in subcutaneous 4 points injections, then carried out mouse tail vein injection pertussis poison in 0 hour and 24 hours
Plain (PTX).The date is fixed for the 0th day for inoculation, date thereafter is denoted as the 1st respectively, 2,3 ... 12 days.
Started tail vein injection at the 11st day；A concentration of 20nmol of HPPS-DIRBOA made from injection embodiment 3 (are pressed
It is calculated according to DIRBOA concentration)；Mouse is placed for 24 hours, is carried out later using the integral fluorescence imaging system that laboratory is voluntarily arranged in pairs or groups
Fluorescence imaging.
Control groups are set as normal mouse and carry out tail vein injection HPPS-DIRBOA, other operations such as experimental group.
It can significantly observe that the mouse to induce an illness can significantly observe in early stage by the imaging results to mouse
The signal of nano-carrier, and the signal is in the immunocyte of extraction, as shown in Figure 8.The living imaging result from Fig. 8
As can be seen that for the mouse not induced an illness, while injection carries the nano-lipid of fluorescent dye DIRBOA
In body, only induction of in the brain of EAE model mices contain a large amount of fluorescence signals, and do not contained in normal mouse DIRBOA letter
Number；By the way that the in vitro imaging that the brain and spinal cord of the mouse of induction EAE diseases and normal mouse are dissected can be seen that only
Brain and spinal cord in the mouse of only EAE disease induction model contain a large amount of DIRBOA signals, in order to confirm these signals
Source is detached by the spinal cord to mouse and the immunocyte of brain, then carries out the fluorescence signal acquisition of cell level,
It can be found that most of fluorescence signal is predominantly located in the immunocyte of extraction.
The CX3CR1-GFP chimeric mices of induction EAE models after HPPS-DIRBOA is injected carry out brain frost and cut for 24 hours
Piece, from Fig. 9 it can be seen that DIRBOA fluorescence signals focus primarily upon inflammatory monocyte and in neutrophil leucocyte, explanation is received
Mizhi plastid is mainly absorbed by inflammatory monocyte and neutrophil leucocyte, while it is possible also to illustrate that nano liposomes play curative effect
It is related to targeting this two classes cell.
<110>The Central China University of Science and Technology;
Ezhou Industrial Technology Research Institute of the Central China University of Science and Technology
<120>A kind of nano liposomes for carrying polypeptide and its preparation method and application
<130> P1711487C
<140> 2017114482304
<141> 2017-12-27
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 21
<212> PRT
<213> Mus Musculus
<220>
<223> R4F
<400> 1
Phe Ala Glu Lys Phe Lys Glu Ala Val Lys Asp Tyr Phe Ala Lys Phe
1 5 10 15
Trp Asp Gly Ser Gly
20
Claims (10)
1. a kind of nano liposomes for carrying polypeptide, which is characterized in that it is 30 that the nano liposomes, which include molar ratio,:(0.5~
1):8 phosphatide, cholesteryl ester and target polypeptide, the target polypeptide are amino acid sequence as shown in SEQ ID NO.1
R4F。
2. nano liposomes as described in claim 1, which is characterized in that the nano liposomes further include lipophilicity carbocyanine
Dyestuff；Preferably, the molar ratio of the lipophilicity carbonyl cyanine dye, phosphatide, cholesteryl ester and R4F are 2:30:1:8.
3. nano liposomes as described in claim 1, which is characterized in that the nano liposomes further include curcumin, described
The molar ratio of curcumin and phosphatide, cholesteryl ester and R4F be (5~10):30:(0.5~1):8；Preferably, the nanometer fat
Plastid is made of curcumin, phosphatide, cholesteryl ester and R4F.
4. nano liposomes as claimed in claim 3, which is characterized in that curcumin, phosphatide, cholesteryl ester and the R4F
Molar ratio be 10:30:1:8.
5. such as Claims 1 to 4 any one of them nano liposomes, which is characterized in that the phosphatide is two myristoyl phosphorus
Phosphatidylcholine；The cholesteryl ester is cholesterol acid ester.
6. the preparation method of nano liposomes as claimed in claim 1 or 2, which is characterized in that the preparation method is using existing
The film dispersion method of liposome.
7. the preparation method of nano liposomes as claimed in claim 6, which is characterized in that it includes the following steps：
1) phosphatide and cholesteryl ester are dissolved in the container containing organic solvent, mixing resulting mixture；
2) said mixture is made to form thin film in the container bottom；
3) buffer solution is added in, above-mentioned film is fully resuspended, forms uniform suspension；
4) ultrasound becomes to above-mentioned suspension and clarifies, and adds in polypeptide, mixing to obtain the final product；
Preferably, the phosphatide is dimyristoyl phosphatidyl choline, and the cholesteryl ester is cholesterol acid ester.
8. the preparation method of nano liposomes as claimed in claim 7, which is characterized in that the step 1), which further includes, adds in ginger
The molar ratio of flavine, the curcumin and phosphatide, cholesteryl ester and R4F is (5~10):30:(0.5~1):8；Preferably,
The curcumin, phosphatide, cholesteryl ester and R4F molar ratio be 10:30:1:8；Preferably, 5) step, which further includes, surpasses
It filters off except free curcumin and polypeptide；It is highly preferred that the ultrafiltration is carried out using 30KD super filter tubes.
9. such as claim 6~8 any one of them preparation method, which is characterized in that the organic solvent is chloroform；It is preferred that
Ground, the film is dried up by nitrogen to be formed or is made after organic solvent is evaporated under reduced pressure with Rotary Evaporators；Preferably, the buffering
Liquid is the phosphate buffer of pH6.5~7.5.
10. nano liposomes as claimed in claim 1 or 2 are in the drug for preparing diagnostic test spontaneity encephalomyelitis
Using or claim 3~5 any one of them nano liposomes in the medicine for preparing Experiment on therapy spontaneity encephalomyelitis
Application in object.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711448230.4A CN108143719B (en) | 2017-12-27 | 2017-12-27 | Polypeptide-carrying nanoliposome and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711448230.4A CN108143719B (en) | 2017-12-27 | 2017-12-27 | Polypeptide-carrying nanoliposome and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108143719A true CN108143719A (en) | 2018-06-12 |
| CN108143719B CN108143719B (en) | 2022-01-25 |
Family
ID=62463319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711448230.4A Active CN108143719B (en) | 2017-12-27 | 2017-12-27 | Polypeptide-carrying nanoliposome and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108143719B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109248309A (en) * | 2018-10-29 | 2019-01-22 | 深圳职业技术学院 | A kind of VLPVP that contains receives the preparation method of rouge body |
| CN110859970A (en) * | 2019-11-03 | 2020-03-06 | 复旦大学 | Cyanine dye FD-1080J-aggregate and preparation method and application thereof |
| CN115404212A (en) * | 2022-08-18 | 2022-11-29 | 三峡大学 | Small-particle-size nano cell membrane vesicle, preparation method, composition and kit |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102027019A (en) * | 2007-12-12 | 2011-04-20 | 大学健康网络 | High-density lipoprotein-like peptide-phospholipid scaffold (''HPPS'') nanoparticles |
| CN102766215A (en) * | 2012-06-07 | 2012-11-07 | 华中科技大学 | Polypeptide with function of synergic targeting treatment of nasopharyngeal carcinoma, nanoparticle carrying the polypeptide and application thereof |
| CN102895188A (en) * | 2012-09-24 | 2013-01-30 | 暨南大学 | Borneol-curcumin liposome and preparation method and application thereof |
-
2017
- 2017-12-27 CN CN201711448230.4A patent/CN108143719B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102027019A (en) * | 2007-12-12 | 2011-04-20 | 大学健康网络 | High-density lipoprotein-like peptide-phospholipid scaffold (''HPPS'') nanoparticles |
| CN102766215A (en) * | 2012-06-07 | 2012-11-07 | 华中科技大学 | Polypeptide with function of synergic targeting treatment of nasopharyngeal carcinoma, nanoparticle carrying the polypeptide and application thereof |
| CN102895188A (en) * | 2012-09-24 | 2013-01-30 | 暨南大学 | Borneol-curcumin liposome and preparation method and application thereof |
Non-Patent Citations (11)
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109248309A (en) * | 2018-10-29 | 2019-01-22 | 深圳职业技术学院 | A kind of VLPVP that contains receives the preparation method of rouge body |
| CN110859970A (en) * | 2019-11-03 | 2020-03-06 | 复旦大学 | Cyanine dye FD-1080J-aggregate and preparation method and application thereof |
| CN115404212A (en) * | 2022-08-18 | 2022-11-29 | 三峡大学 | Small-particle-size nano cell membrane vesicle, preparation method, composition and kit |
| CN115404212B (en) * | 2022-08-18 | 2024-03-12 | 三峡大学 | Small-particle-size nano cell membrane vesicle, preparation method, composition and kit |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108143719B (en) | 2022-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Boge et al. | Cubosomes for topical delivery of the antimicrobial peptide LL-37 | |
| Yang et al. | Chitosan mediated solid lipid nanoparticles for enhanced liver delivery of zedoary turmeric oil in vivo | |
| US6592894B1 (en) | Hydrogel-isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules | |
| JPH06510024A (en) | Pharmaceutical preparations and methods | |
| CN110101684A (en) | A kind of cellular membrane biomimetic nano particle and its preparation method and application of bio-orthogonal targeting | |
| CN107802646A (en) | A kind of anti-tumor medicine | |
| CN108143719A (en) | A kind of nano liposomes for carrying polypeptide and its preparation method and application | |
| CN108815160A (en) | A kind of rapamycin liposome nano granule and preparation method thereof | |
| Guo et al. | Doxorubicin-loaded natural daptomycin micelles with enhanced targeting and anti-tumor effect in vivo | |
| CN110025593A (en) | Cell microcapsule, the cell microcapsule for being loaded with anticancer drug, preparation method and application | |
| CN101602791B (en) | Integrin receptor target lipidosome drug carrier, preparation method and application thereof | |
| Lee et al. | Nanomedicine–Nanoemulsion Formulation Improves Safety and Efficacy of the Anti-Cancer Drug Paclitaxel According to Preclinical Assessment | |
| AU3111401A (en) | New cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules | |
| WO2014034669A1 (en) | Lipid membrane structure including bacterial cell component having dispersibility in non-polar solvent, and method for producing same | |
| CN113876964A (en) | Tumor cell membrane drug-loading system and construction method and application thereof | |
| CN102552145A (en) | Preparation method of artificial liposome | |
| CN105770912A (en) | Drug-loading ATP sensitive liposome with tumor near infrared fluorescence development function and preparation method of drug-loading ATP sensitive liposome | |
| CN105919935A (en) | Sorafenib medicinal lipid nanosuspension and preparation method thereof | |
| CN104173288B (en) | Clarithromycin ion pair lipidosome injection and preparation method thereof | |
| CN113456832A (en) | Transferrin-modified antibody-entrapped nanoparticle and application thereof | |
| CN105663060B (en) | A kind of dianhydrogalactitol lipidosome freeze-dried injection and preparation method thereof | |
| Zhang et al. | Nano-lipid contrast agent combined with ultrasound-guided sgb in nursing treatment of lymphedema after breast cancer surgery | |
| CN110013543A (en) | ApoD is preparing the application in anti-parkinson drug, ApoD preparation and preparation method thereof | |
| CN113288871B (en) | Pharmaceutical composition liposome formulations for modulation of epigenetic and immune checkpoints | |
| CN115463110B (en) | Cholic acid modified oral paclitaxel nanoparticle, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |